Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Bladder Cancer, November 2023

Free Subscription


Abstracts

Retrieve all available abstracts of the following 225 articles:
HTML format


 

Single Articles

  1. CHEN Z, Deng K, Sun L, Qu L, et al
    3D laparoscopic treatment of bladder cancer with pelvic multi-organ invasion: a case report and literature review.
    Front Oncol. 2023;13:1249389.
    PubMed    
    Abstract available

  2. GARIONI M, Tschan VJ, Blukacz L, Nuciforo S, et al
    Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer.
    NPJ Precis Oncol. 2023;7:112.
    PubMed    
    Abstract available

  3. WEI L, Ji L, Han S, Xu M, et al
    Construction and Validation of a Prognostic Model of Metabolism-Related Genes Driven by Somatic Mutation in Bladder Cancer.
    Front Biosci (Landmark Ed). 2023;28:242.
    PubMed    
    Abstract available

  4. KIM SW, Yu H, Kim Y, Nam K, et al
    HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: A retrospective cohort study.
    Int J Surg. 2023 Nov 2. doi: 10.1097/JS9.0000000000000859.
    PubMed    
    Abstract available

  5. QIN C, Tian Q, Zhou H, Qin Y, et al
    Detecting Muscle Invasion of Bladder Cancer: An Application of Diffusion Kurtosis Imaging Ratio and Vesical Imaging-Reporting and Data System.
    J Magn Reson Imaging. 2023 Nov 2. doi: 10.1002/jmri.29053.
    PubMed    
    Abstract available

  6. HU WM, Li M, Ning JZ, Tang YQ, et al
    FAM171B stabilizes vimentin and enhances CCL2-mediated TAM infiltration to promote bladder cancer progression.
    J Exp Clin Cancer Res. 2023;42:290.
    PubMed    
    Abstract available

  7. SHUAI H, Duan X, Zhou JJ, Liu Y, et al
    Effect of the TERT mutation on the prognosis of patients with urothelial carcinoma: a systematic review and meta-analysis.
    BMC Urol. 2023;23:177.
    PubMed    
    Abstract available

  8. UEKI Y, Kobayashi K, Hashimoto K, Tanaka T, et al
    [Urological Comorbidities in an HIV-Infected Patient: A Case Report].
    Hinyokika Kiyo. 2023;69:299-303.
    PubMed    
    Abstract available

  9. PATEL HD, Naha U, Chen VS, Ko C, et al
    Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle-Invasive Bladder Cancer: Elective and Eligibility Factors Impacting Utilization.
    Urol Pract. 2023 Oct 30:101097UPJ0000000000000467.
    PubMed    
    Abstract available

  10. SINGH R, Sharma G, Priyadarshi S, Fauzdar G, et al
    Prognostic significance of preoperative pyuria & Neutrophil to lymphocyte ratio in patients with non-muscle-invasive bladder cancer: A prospective cohort study.
    Urologia. 2023 Nov 1:3915603231203780. doi: 10.1177/03915603231203780.
    PubMed    
    Abstract available

  11. SAVCHENKO E, Rosenfeld A, Bunimovich-Mendrazitsky S
    Mathematical modeling of BCG-based bladder cancer treatment using socio-demographics.
    Sci Rep. 2023;13:18754.
    PubMed    
    Abstract available

  12. ZHOU Q, Chen X, Chen Q, Hao L, et al
    Factors Influencing Quality of Life and Functional Outcomes in Patients With Bladder Cancer.
    Cancer Control. 2023;30:10732748231212353.
    PubMed    
    Abstract available

  13. NARAYAN VM, Siolas D, Meadows ES, Turzhitsky V, et al
    Evaluation of a Natural Language Processing Model to Identify and Characterize Patients in the United States With High-Risk Non-Muscle-Invasive Bladder Cancer.
    JCO Clin Cancer Inform. 2023;7:e2300096.
    PubMed    
    Abstract available

  14. DA SILVA AC, Scholl JN, de Fraga Dias A, Weber AF, et al
    Preclinical evaluation of bozepinib in bladder cancer cell lines: modulation of the NPP1 enzyme.
    Purinergic Signal. 2023 Oct 31. doi: 10.1007/s11302-023-09975.
    PubMed    
    Abstract available

  15. ZAZA MMA, Salem TAE, El-Sadat AM, Hassan Ali M, et al
    Comparative study between mitomycin C versus Bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer.
    Urologia. 2023 Oct 31:3915603231206603. doi: 10.1177/03915603231206603.
    PubMed    
    Abstract available

  16. ABOU CHAKRA M, Shore ND, Dillon R, O'Donnell MA, et al
    US Clinical Practice Patterns of Intravesical Chemotherapy for Bacillus Calmette-Guerin-Unresponsive and Bacillus Calmette-Guerin-Exposed Nonmuscle-Invasive Bladder Cancer.
    Urol Pract. 2023 Oct 30:101097UPJ0000000000000481.
    PubMed    
    Abstract available

  17. LV Z, Hou J, Wang Y, Wang X, et al
    Knowledge-map analysis of bladder cancer immunotherapy.
    Hum Vaccin Immunother. 2023;19:2267301.
    PubMed    
    Abstract available

  18. FAWZY MS, El Faiomy ARM, El Desoky AMZ, Hussein S, et al
    The relationship between DNA methyltransferase 3B (DNMT3B) and miR 124-3pa expressions in bladder cancer tissues.
    Mol Biol Rep. 2023 Oct 30. doi: 10.1007/s11033-023-08818.
    PubMed    
    Abstract available

  19. ZHAO L, Han D, Zhu J, Bi D, et al
    The RNA m6A-Binding Protein YTHDC1 Is Downregulated and Associated With M2 Macrophage Infiltration in Muscle-Invasive Bladder Cancer.
    Clin Med Insights Oncol. 2023;17:11795549231203150.
    PubMed    
    Abstract available

  20. BAZARGAN S, Bunch B, Ojwang' AME, Blauvelt J, et al
    Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer.
    Front Immunol. 2023;14:1275375.
    PubMed    
    Abstract available

  21. LU J, Zhou W, He H, Chen J, et al
    Duodenal stenosis caused by locally advanced upper tract urothelial carcinoma: a case report.
    J Int Med Res. 2023;51:3000605231206958.
    PubMed    
    Abstract available

  22. LIU J, Lai S, Wu P, Wang J, et al
    Systematic oxidative stress indices predicts prognosis in patients with urothelial carcinoma of the upper urinary tract after radical nephroureterectomy.
    Eur J Med Res. 2023;28:469.
    PubMed    
    Abstract available

  23. LIN JH, Hung CH, Huang YC, Chen CS, et al
    The p38-MITOGEN-ACTIVATED PROTEIN KINASE Signaling Pathway Is Involved in Leonurus artemisia Extract-Induced Inhibition of the Proliferation of Human Bladder Cancer BFTC-905 Cells via G1/G0 Arrest and Causes Apoptosis In Vitro.
    Pharmaceuticals (Basel). 2023;16:1338.
    PubMed    
    Abstract available

  24. ALI W, Xiao W, Jacobs D, Kajdacsy-Balla A, et al
    Survival and Enrichment Analysis of Epithelial-Mesenchymal Transition Genes in Bladder Urothelial Carcinoma.
    Genes (Basel). 2023;14:1899.
    PubMed    
    Abstract available

  25. EMINAGA O, Leyh-Bannurah SR, Shariat SF, Krabbe LM, et al
    Artificial Intelligence Reveals Distinct Prognostic Subgroups of Muscle-Invasive Bladder Cancer on Histology Images.
    Cancers (Basel). 2023;15:4998.
    PubMed    
    Abstract available

  26. POTTGEN C, Hoffmann C, Gauler T, Guberina M, et al
    Fractionation versus Adaptation for Compensation of Target Volume Changes during Online Adaptive Radiotherapy for Bladder Cancer: Answers from a Prospective Registry.
    Cancers (Basel). 2023;15:4933.
    PubMed    
    Abstract available

  27. HU CY, Hung CF, Chen PC, Hsu JY, et al
    Oct4 and Hypoxia Dual-Regulated Oncolytic Adenovirus Armed with shRNA-Targeting Dendritic Cell Immunoreceptor Exerts Potent Antitumor Activity against Bladder Cancer.
    Biomedicines. 2023;11:2598.
    PubMed    
    Abstract available

  28. ALFAQIH MA, Elsalem L, Nusier M, Mhedat K, et al
    Serum Leptin Receptor and the rs1137101 Variant of the LEPR Gene Are Associated with Bladder Cancer.
    Biomolecules. 2023;13:1498.
    PubMed    
    Abstract available

  29. YU SH, Kim SS, Lee H, Kim S, et al
    Somatic Mutation of the Non-Muscle-Invasive Bladder Cancer Associated with Early Recurrence.
    Diagnostics (Basel). 2023;13:3201.
    PubMed    
    Abstract available

  30. FRISHBERG A, Milman N, Alpert A, Spitzer H, et al
    Reconstructing disease dynamics for mechanistic insights and clinical benefit.
    Nat Commun. 2023;14:6840.
    PubMed    
    Abstract available

  31. LI Z, Zhou L, Lin C, Pan X, et al
    Corrigendum to "MiR-302b regulates cell functions and acts as a potential biomarker to predict recurrence in bladder cancer" [Life Sciences, 209 (2018) 15-23].
    Life Sci. 2023 Oct 25:122169. doi: 10.1016/j.lfs.2023.122169.
    PubMed    


  32. YUE M, Yang Z, Sun J, Liu Z, et al
    A candidate prognostic biomarker: TFEB inhibits tumor progression via elevating CDKN1A in bladder cancer.
    Int Immunopharmacol. 2023;125.
    PubMed    
    Abstract available

  33. ZEMLA J, Szydlak R, Gajos K, Kozlowski L, et al
    Plasma Treatment of PDMS for Microcontact Printing (muCP) of Lectins Decreases Silicone Transfer and Increases the Adhesion of Bladder Cancer Cells.
    ACS Appl Mater Interfaces. 2023 Oct 27. doi: 10.1021/acsami.3c09195.
    PubMed    
    Abstract available

  34. VARCHULOVA NOVAKOVA Z, Kuniakova M, Ziaran S, Harsanyi S, et al
    Molecular Biomarkers of Bladder Cancer: A Mini-Review.
    Physiol Res. 2023;72.
    PubMed    
    Abstract available

  35. PARK HK
    Do Histology and Primary Tumor Location Influence Metastatic Patterns in Bladder Cancer?
    Curr Oncol. 2023;30:9078-9089.
    PubMed    
    Abstract available

  36. PRIJOVIC N, Acimovic M, Santric V, Stankovic B, et al
    The Impact of Variant Histology in Patients with Urothelial Carcinoma Treated with Radical Cystectomy: Can We Predict the Presence of Variant Histology?
    Curr Oncol. 2023;30:8841-8852.
    PubMed    
    Abstract available

  37. GLUTH L, Ochsenfarth C, Pham PNV, Wischermann JM, et al
    Influence of the Anesthetic Technique on Circulating Extracellular Vesicles in Bladder Cancer Patients Undergoing Radical Cystectomy: A Prospective, Randomized Trial.
    Cells. 2023;12:2503.
    PubMed    
    Abstract available

  38. SHAN Z, Tang W, Shi Z, Shan T, et al
    Ferroptosis: An Emerging Target for Bladder Cancer Therapy.
    Curr Issues Mol Biol. 2023;45:8201-8214.
    PubMed    
    Abstract available

  39. STARRETT GJ, Foster H, Sigel K, Liu Y, et al
    Brief Report: The Virome of Bladder Tumors Arising in People Living With HIV.
    J Acquir Immune Defic Syndr. 2023;94:337-340.
    PubMed    
    Abstract available

  40. LOPEZ-BELTRAN A, Gonzalez-Peramato P, Sanz-Ortega J, Prieto Cuadra JD, et al
    [Practical aspects of PD-L1 assessment in the treatment of urothelial carcinoma: Consensus of the uropathology group of the SEAP].
    Rev Esp Patol. 2023;56:261-270.
    PubMed    
    Abstract available

  41. KLUMPER N, Wust L, Saal J, Ralser DJ, et al
    PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.
    Oncoimmunology. 2023;12:2267744.
    PubMed    
    Abstract available

  42. VARADI M, Horvath O, Modos O, Fazekas T, et al
    Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study.
    Sci Rep. 2023;13:17378.
    PubMed    
    Abstract available

  43. MARAZ A, Nagy B, Macher T, Jesko J, et al
    Nationwide Study of Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in Hungary.
    Adv Ther. 2023;40:5475-5488.
    PubMed    
    Abstract available

  44. WANG H, Ding Y, He Y, Yu Z, et al
    LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial dynamics via the MAPK pathway.
    Arch Biochem Biophys. 2023;748:109783.
    PubMed    
    Abstract available

  45. LI Y, Wu Q, Lv J, Gu J, et al
    A comprehensive pan-cancer analysis of CDH5 in immunological response.
    Front Immunol. 2023;14:1239875.
    PubMed    
    Abstract available

  46. LI M, Fu X, Zu X, Chen J, et al
    Modified Tubeless Ureterocutaneostomy in High-Risk Patients After Radical Cystectomy and its Long-Term Clinical Outcomes.
    Technol Cancer Res Treat. 2023;22:15330338231192906.
    PubMed    
    Abstract available

  47. SACHDEVA S, Suresh PK, Basavaiah SH, Sahu KK, et al
    p16 expression in urothelial carcinoma: Experience from a tertiary care center in coastal South India.
    J Cancer Res Ther. 2023;19:1330-1334.
    PubMed    
    Abstract available

  48. LIANG H, Yang Q, Zhang Y, Sun H, et al
    Development and validation of a predictive model for the diagnosis of bladder tumors using narrow band imaging.
    J Cancer Res Clin Oncol. 2023;149:15867-15877.
    PubMed    
    Abstract available

  49. SHRIVASTAVA N, Jena R, Choudhary GR, Bhargava P, et al
    Correlation between androgen and estrogen receptor expression and clinicopathologic features in carcinoma urinary bladder.
    J Cancer Res Clin Oncol. 2023;149:15795-15804.
    PubMed    
    Abstract available

  50. ISCAIFE A, Socarras MR, Gonzalez LL, Rivas JG, et al
    En Bloc Resection of Bladder Tumors (ERBT) using different lasers - Hybrid and Holmium Laser.
    Int Braz J Urol. 2023;49:783-784.
    PubMed    
    Abstract available

  51. GAYA JM, Uleri A, Sanz I, Basile G, et al
    Robot-assisted radical cystectomy and ileal conduit with Hugo(TM) RAS system: feasibility, setting and perioperative outcomes.
    Int Braz J Urol. 2023;49:787-788.
    PubMed    
    Abstract available

  52. PIVOVARCIKOVA K, Pitra T, Alaghehbandan R, Buchova K, et al
    Lynch syndrome-associated upper tract urothelial carcinoma frequently occurs in patients older than 60 years: an opportunity to revisit urology clinical guidelines.
    Virchows Arch. 2023;483:517-526.
    PubMed    
    Abstract available

  53. KIM JM, Lee J, Sung SH
    Application of The Paris System in neobladder washing cytology: Comparison between the original diagnosis and correlation with histopathology.
    Diagn Cytopathol. 2023;51:744-750.
    PubMed    
    Abstract available

  54. FOLARIN OS, Siddiqui MT
    Are we on track for diagnosing high-grade urothelial carcinoma with a minimum quantity of five malignant cells in lower tract specimens? Critical analysis of The Paris System Quantitation Criteria.
    Cancer Cytopathol. 2023;131:708-715.
    PubMed    
    Abstract available

  55. WANG Y, Yan S, Liu Y, Yan Z, et al
    Dynamic viral integration patterns actively participate in the progression of BK polyomavirus-associated diseases after renal transplantation.
    Am J Transplant. 2023;23:1694-1708.
    PubMed    
    Abstract available

  56. GOUBET AG, Rouanne M, Derosa L, Kroemer G, et al
    From mucosal infection to successful cancer immunotherapy.
    Nat Rev Urol. 2023;20:682-700.
    PubMed    
    Abstract available

  57. REN K, Feng J, Bi H, Sun Q, et al
    AFM-Based Poroelastic@Membrane Analysis of Cells and its Opportunities for Translational Medicine.
    Small. 2023;19:e2303610.
    PubMed    
    Abstract available

  58. GRANT CR, de Kouchkovsky D, Kalebasty AR, Mar N, et al
    Drug extravasation with Enfortumab vedotin.
    J Oncol Pharm Pract. 2023;29:1789-1792.
    PubMed    
    Abstract available

  59. PEI L, Yan D, He Q, Kong J, et al
    LncRNA MIR4435-2HG drives cancer progression by modulating cell cycle regulators and mTOR signaling in stroma-enriched subtypes of urothelial carcinoma of the bladder.
    Cell Oncol (Dordr). 2023;46:1509-1527.
    PubMed    
    Abstract available

  60. JONES H, Bhakta A, Jia L, Wojciechowski D, et al
    An Unusual Presentation of Metastatic BK Virus-Associated Urothelial Carcinoma Arising in the Allograft, Persisting After Transplant Nephrectomy.
    Int J Surg Pathol. 2023;31:1586-1592.
    PubMed    
    Abstract available

  61. PESCIA C, Pini G, Lopez G, Malfatto M, et al
    A Rare Case of Urinary Bladder Hamartoma Clinically Mimicking an Urothelial Carcinoma: A Case Report and Review of the Literature.
    Int J Surg Pathol. 2023;31:1572-1579.
    PubMed    
    Abstract available

  62. MINATO H, Yoshikawa A, Tsuyama S, Katayanagi K, et al
    Ureteral Metastasis of Colonic Adenocarcinoma with Enteroblastic Differentiation: A Rare Case to be Distinguished from Clear Cell Adenocarcinoma of the Urinary Tract.
    Int J Surg Pathol. 2023;31:1553-1558.
    PubMed    
    Abstract available

  63. METHODS IN MEDICINE CAM
    Retracted: Computed Tomography Image Features under Deep Learning Algorithm Applied in Staging Diagnosis of Bladder Cancer and Detection on Ceramide Glycosylation.
    Comput Math Methods Med. 2023;2023:9842436.
    PubMed    
    Abstract available

  64. AND BIOMECHANICS AB
    Retracted: Applications of Bladder Cancer Data Using a Modified Log-Logistic Model.
    Appl Bionics Biomech. 2023;2023:9789308.
    PubMed    
    Abstract available

  65. OGURA R, Ito S, Ueda T, Gabata Y, et al
    Screening for a practical method to monitor the status of patients with metastatic bladder cancer at the circulating cell-gene level.
    Sci Rep. 2023;13:19517.
    PubMed    
    Abstract available

  66. LAURIE MA, Zhou SR, Islam MT, Shkolyar E, et al
    Bladder Cancer and Artificial Intelligence: Emerging Applications.
    Urol Clin North Am. 2024;51:63-75.
    PubMed    
    Abstract available

  67. CAO Y, Zou Z, Wu X, Li W, et al
    LUCAT1 inhibits ferroptosis in bladder cancer by regulating the mRNA stability of STAT3.
    Gene. 2023 Nov 7:147974. doi: 10.1016/j.gene.2023.147974.
    PubMed    
    Abstract available

  68. WANG X, Wang Z, Wei Q, Wang H, et al
    Anoikis-associated signatures predict prognosis and immune response in bladder cancer.
    Epigenomics. 2023 Nov 9. doi: 10.2217/epi-2023-0240.
    PubMed    
    Abstract available

  69. FARNAZ T, Bhattacharjee P, Ahamad MSU, Rima SA, et al
    The Prevalence of p16 Expression in Urothelial Bladder Cancer in a Tertiary Care Hospital of Chattogram, Bangladesh.
    Iran J Pathol. 2023;18:306-311.
    PubMed    
    Abstract available

  70. MOHAMED NE, Leung TM, Benn EK, Korn TG, et al
    Depression and anxiety among patients treated for bladder cancer: examining clinical, demographic, and psychosocial predictors.
    Am J Clin Exp Urol. 2023;11:401-413.
    PubMed    
    Abstract available

  71. JIA ZY, Yang F, Zhang W, Li WW, et al
    Application of contrast-enhanced ultrasound in renal space-occupying lesion puncture biopsy.
    BMC Med Imaging. 2023;23:178.
    PubMed    
    Abstract available

  72. TANIUCHI M, Yanagi M, Kiriyama T, Akatsuka J, et al
    Primary leiomyoma of the bladder radiologically mimicking a retroperitoneal tumor - a case report.
    J Med Invest. 2023;70.
    PubMed    
    Abstract available

  73. CUI A, Li X, Ma X, Song Z, et al
    Quantitative transcriptomic and proteomic analysis reveals corosolic acid inhibiting bladder cancer via suppressing cell cycle and inducing mitophagy in vitro and in vivo.
    Toxicol Appl Pharmacol. 2023 Nov 6:116749. doi: 10.1016/j.taap.2023.116749.
    PubMed    
    Abstract available

  74. CHEN B, Shu B, Liu Z, Zhu J, et al
    The diagnostic value of fluorescence in situ hybridization in secondary electroresection of bladder cancer.
    Bladder (San Franc). 2023;10:e21200006.
    PubMed    
    Abstract available

  75. GU Y, Lu Y, Xiong Y, Zhan X, et al
    Advances in the bladder cancer research using 3D culture models.
    Bladder (San Franc). 2023;10:e21200005.
    PubMed    
    Abstract available

  76. FU W, Zhang X
    Laparoscopic and Robotic-Assisted Extended Pelvic Lymph Node Dissection for Invasive Bladder Cancer: A Review.
    Bladder (San Franc). 2023;10:e21200004.
    PubMed    
    Abstract available

  77. LIU T, Gu J, Li C, Guo M, et al
    Alternative polyadenylation-related genetic variants contribute to bladder cancer risk.
    J Biomed Res. 2023 Nov 15:1-13. doi: 10.7555/JBR.37.20230063.
    PubMed    
    Abstract available

  78. WEI X, Jiang Y, Yang G, Chang T, et al
    MicroRNA-367-3p directly targets RAB23 and inhibits proliferation, migration and invasion of bladder cancer cells and increases cisplatin sensitivity.
    J Cancer Res Clin Oncol. 2023 Nov 8. doi: 10.1007/s00432-023-05484.
    PubMed    
    Abstract available

  79. CHEN H, Ma L, Yang W, Li Y, et al
    POLR3G promotes EMT via PI3K/AKT signaling pathway in bladder cancer.
    FASEB J. 2023;37:e23260.
    PubMed    
    Abstract available

  80. WANG J, Luo J, Wu X, Li Z, et al
    WTAP enhances the instability of SYTL1 mRNA caused by YTHDF2 in bladder cancer.
    Histol Histopathol. 2023 Oct 23:18671. doi: 10.14670.
    PubMed    
    Abstract available

  81. LI G, Song Z, Ru Y, Zhang J, et al
    Small-molecule nanoprodrug with high drug loading and EGFR, PI3K/AKT dual-inhibiting properties for bladder cancer treatment.
    Exploration (Beijing). 2023;3:20220141.
    PubMed    
    Abstract available

  82. JEON J, Ha JS, Shin SJ, Ham WS, et al
    Differences in clinical features between focal and extensive types of cystitis glandularis in patients without a previous history of urinary tract malignancy.
    Investig Clin Urol. 2023;64:597-605.
    PubMed    
    Abstract available

  83. DURSUN F, Elshabrawy A, Wang H, Kaushik D, et al
    Impact of rural residence on the presentation, management and survival of patients with non-metastatic muscle-invasive bladder carcinoma.
    Investig Clin Urol. 2023;64:561-571.
    PubMed    
    Abstract available

  84. EL AZAB A, Abdelbary A, El Faqeh M Okasha A, Aboulkassem H, et al
    The effect of immediate neoadjuvant electromotive instillation of mitomycin C with Bacillus Calmette-Guerin versus BCG alone in non-muscle-invasive bladder cancer: A randomized controlled trial.
    Investig Clin Urol. 2023;64:554-560.
    PubMed    
    Abstract available

  85. JAI-UA C, Limpaiboon C, Siriboonrid S, Binsri N, et al
    Accuracy of Vesical Imaging-Reporting and Data System for muscle-invasive bladder cancer detection from multiparametric magnetic resonance imaging.
    Investig Clin Urol. 2023;64:546-553.
    PubMed    
    Abstract available

  86. JANEV A, Ramuta TZ, Jerman UD, Obradovic H, et al
    Human amniotic membrane inhibits migration and invasion of muscle-invasive bladder cancer urothelial cells by downregulating the FAK/PI3K/Akt/mTOR signalling pathway.
    Sci Rep. 2023;13:19227.
    PubMed    
    Abstract available

  87. SINGH V, Singh MK, Jain M, Pandey AK, et al
    The relationship between BCG immunotherapy and oxidative stress parameters in patients with nonmuscle invasive bladder cancer.
    Urol Oncol. 2023 Nov 4:S1078-1439(23)00321-6. doi: 10.1016/j.urolonc.2023.
    PubMed    
    Abstract available

  88. ADEMAJ A, Puric E, Marder D, Timm O, et al
    Radiotherapy combined with deep regional hyperthermia in elderly and frail patients with muscle-invasive bladder cancer: quality analysis of hyperthermia and impact on clinical results.
    Int J Hyperthermia. 2023;40:2275540.
    PubMed    
    Abstract available

  89. RIVEROS C, Ranganathan S, Haque W, Huang E, et al
    Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation.
    Can Urol Assoc J. 2023 Oct 23. doi: 10.5489/cuaj.8386.
    PubMed    
    Abstract available

  90. ARAI Y, Goto Y, Sazuka T, Fujimoto A, et al
    A case of bladder cancer after bilateral lung transplantation following bone marrow transplantation.
    IJU Case Rep. 2023;6:471-474.
    PubMed    
    Abstract available

  91. KARAN C, Yaren A, Demirel BC, Dogan T, et al
    Pretreatment PLR Is Preferable to NLR and LMR as a Predictor in Locally Advanced and Metastatic Bladder Cancer.
    Cancer Diagn Progn. 2023;3:706-715.
    PubMed    
    Abstract available

  92. XU X, Huang Y, Liu Y, Cai Q, et al
    Multiparametric MRI-based VI-RADS: can it predict 1- to 5-year recurrence of bladder cancer?
    Eur Radiol. 2023 Nov 6. doi: 10.1007/s00330-023-10387.
    PubMed    
    Abstract available

  93. ZHANG L, Shao G, Shao J, Zhao J, et al
    Corrigendum to "PRMT5-activated c-Myc promote bladder cancer proliferation and invasion through up-regulating NF-kappaB pathway" [Tissue Cell 76 (2022) 101788].
    Tissue Cell. 2023 Nov 1:102221. doi: 10.1016/j.tice.2023.102221.
    PubMed    


  94. SORIA F, Rosazza M, Livoti S, Dutto D, et al
    Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guerin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study.
    Eur Urol Focus. 2023 Nov 1:S2405-4569(23)00236-5. doi: 10.1016/j.euf.2023.
    PubMed    
    Abstract available

  95. YANG M, Wang J, Quan S, Xu Q, et al
    High-precision bladder cancer diagnosis method: 2D Raman spectrum figures based on maintenance technology combined with automatic weighted feature fusion network.
    Anal Chim Acta. 2023;1282:341908.
    PubMed    
    Abstract available

  96. LI D, Liu F, Chen Y, Li P, et al
    Ipsilateral synchronous papillary renal neoplasm with reverse polarity and urothelial carcinoma in a renal transplant recipient: a rare case report with molecular analysis and literature review.
    Diagn Pathol. 2023;18:120.
    PubMed    
    Abstract available

  97. LEDFORD H
    Cancer trial results show power of weaponized antibodies.
    Nature. 2023;623:231-232.
    PubMed    


  98. VAN DER HEIJDEN MS, Sonpavde G, Powles T, Necchi A, et al
    Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
    N Engl J Med. 2023;389:1778-1789.
    PubMed    
    Abstract available

  99. FALTAS B
    A new era in the treatment of urothelial carcinoma.
    Urol Oncol. 2023;41:395-397.
    PubMed    
    Abstract available

  100. KSHATTRY S, Parker TL, Huntington SF
    Peripheral Blasts in a Patient Receiving Chemotherapy.
    JAMA. 2023;330:1581-1582.
    PubMed    


  101. ORTNER G, Somani BK, Guven S, Kitzbichler G, et al
    Experts' recommendations in laser use for the treatment of upper tract urothelial carcinoma: a comprehensive guide by the European Section of Uro-Technology (ESUT) and Training Research in Urological Surgery and Technology (T.R.U.S.T.) group.
    World J Urol. 2023;41:3367-3376.
    PubMed    
    Abstract available

  102. GABRIEL PE, Pinar U, Lenfant L, Parra J, et al
    Perioperative, renal function and oncological outcomes of robot-assisted radical nephroureterectomy for patients with upper tract urothelial carcinoma.
    World J Urol. 2023;41:3001-3007.
    PubMed    
    Abstract available

  103. KLUMPER N, Eckstein M, Kunath F, Heidegger I, et al
    [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
    Urologie. 2023;62:1193-1199.
    PubMed    
    Abstract available

  104. YING Y, Zhang Z, Xing N, Qian Z, et al
    Preoperative urine sediment chromosomal instability level predicts urothelial cancer prognosis.
    Urol Oncol. 2023;41:433.
    PubMed    
    Abstract available

  105. KATIMS AB, Gaffney C, Firouzi S, Yip W, et al
    Feasibility and tissue concordance of genomic sequencing of urinary cytology in upper tract urothelial carcinoma.
    Urol Oncol. 2023;41:433.
    PubMed    
    Abstract available

  106. RESNIK N, Visnjar T, Smrkolj T, Kreft ME, et al
    Selective targeting of lectins and their macropinocytosis in urothelial tumours: translation from in vitro to ex vivo.
    Histochem Cell Biol. 2023;160:435-452.
    PubMed    
    Abstract available

  107. MORENO MF, Kaul S, Fleishman A, Korets R, et al
    Conditional survival following radical cystectomy for urothelial carcinoma of the bladder.
    Urol Oncol. 2023;41:432.
    PubMed    
    Abstract available

  108. HE B, Ye L, Zeng H, Yao J, et al
    Differentiation of urothelial carcinoma and neuroendocrine carcinoma in the urinary bladder based on CT texture analysis.
    Asian J Surg. 2023;46:5053-5054.
    PubMed    


  109. THOMAS J, Sun M, Getz T, Ho B, et al
    Antibody-drug conjugates for urothelial carcinoma.
    Urol Oncol. 2023;41:420-428.
    PubMed    
    Abstract available

  110. XIA M, Xiong S, He F, Li X, et al
    Pelvic lipomatosis with mucinous adenocarcinoma: A case report and literature review.
    Asian J Surg. 2023;46:4889-4890.
    PubMed    


  111. YANG B, Wang D, Niu Y, Liu J, et al
    A carcinoma in situ was inadvertently discovered after surgery for urinary bladder contracture.
    Asian J Surg. 2023;46:4897-4898.
    PubMed    


  112. SONG S, Smith A, Hu B
    The patient experience with localized upper tract urothelial cancer.
    Urol Oncol. 2023;41:431.
    PubMed    
    Abstract available

  113. PINAR U, Calleris G, Grobet-Jeandin E, Grande P, et al
    The role of perioperative chemotherapy for upper tract urothelial carcinoma patients treated with radical nephroureterectomy.
    World J Urol. 2023;41:3205-3230.
    PubMed    
    Abstract available

  114. ATIQ S, Hirshman N, Shariff A, Zhang T, et al
    The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.
    Urol Oncol. 2023;41:410-419.
    PubMed    
    Abstract available

  115. HAN X, Zhang T, Ma Q, Chang R, et al
    Gene expression profiles to analyze the anticancer and carcinogenic effects of arsenic in bladder cancer.
    Am J Transl Res. 2023;15:5984-5996.
    PubMed    
    Abstract available

  116. CAO P, Chen M, Zhang T, Zheng Q, et al
    A sialyltransferases-related gene signature serves as a potential predictor of prognosis and therapeutic response for bladder cancer.
    Eur J Med Res. 2023;28:515.
    PubMed    
    Abstract available

  117. BEDKE J, Black PC, Szabados B, Guerrero-Ramos F, et al
    Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition.
    Urol Oncol. 2023 Nov 13:S1078-1439(23)00342.
    PubMed    
    Abstract available

  118. SHEN C, Chai W, Han J, Zhang Z, et al
    Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
    Front Immunol. 2023;14:1213947.
    PubMed    
    Abstract available

  119. WOO S, Becker AS, Das JP, Ghafoor S, et al
    Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI.
    Cancer Imaging. 2023;23:110.
    PubMed    
    Abstract available

  120. GUO P, Dai P, Yang S, Wang Z, et al
    Engineered Macrophages Tune Intratumoral Cytokines through Precisely Controlled Self-Pyroptosis to Enhance Bladder Cancer Immunotherapy.
    Small. 2023 Nov 14:e2306699. doi: 10.1002/smll.202306699.
    PubMed    
    Abstract available

  121. KLEE M, Roesch MC, Eggers H, Ivanyi P, et al
    Enfortumab vedotin as a salvage option as 5th line therapy for metastatic urothelial bladder cancer.
    Aktuelle Urol. 2023 Nov 14. doi: 10.1055/a-2148-5799.
    PubMed    
    Abstract available

  122. WANG Y, Song Y, Qin C, Zhang C, et al
    Three versus four cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Ann Med. 2023;55:2281654.
    PubMed    
    Abstract available

  123. LIU T, Tang Q, Shan Q, Wang Z, et al
    Identification of potential phytochemical for the inhibition of non-muscle invasive bladder cancer (NMIBC).
    J Biomol Struct Dyn. 2023 Nov 14:1-9. doi: 10.1080/07391102.2023.2280914.
    PubMed    
    Abstract available

  124. YU T, Cui X, Liang N, Wu S, et al
    Postoperative Metachronous Metastasis of Bladder Cancer to Penis: A Case Report.
    Arch Esp Urol. 2023;76:622-626.
    PubMed    
    Abstract available

  125. LI C, Wan Z, Deng Q, Li Z, et al
    Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome.
    Arch Esp Urol. 2023;76:605-621.
    PubMed    
    Abstract available

  126. KRISHNAN J, Symington A, Kernohan N, Bray S, et al
    HMG co-reductase expression and response to intravesical Bacillus Calmette-Guerin in patients with high grade non-muscle invasive urinary bladder cancer receiving statins.
    Scott Med J. 2023 Nov 13:369330231213935. doi: 10.1177/00369330231213935.
    PubMed    
    Abstract available

  127. D'ANDREA VD, Melnick K, Yim K, Ernandez J, et al
    Evidence-Based Analysis of the Critical Steps of Radical Cystectomy for Bladder Cancer.
    J Clin Med. 2023;12:6845.
    PubMed    
    Abstract available

  128. STROBACH D, Haimerl L, Mannell H, Stief CG, et al
    The Characterization of Non-oncologic Chronic Drug Therapy in Bladder Cancer Patients and the Impact on Recurrence-Free and Cancer-Specific Survival: A Prospective Study.
    J Clin Med. 2023;12:6749.
    PubMed    
    Abstract available

  129. XIAO LY, Su YL, Huang SY, Chen YH, et al
    Chitinase 3-like-1 Expression in the Microenvironment Is Associated with Neutrophil Infiltration in Bladder Cancer.
    Int J Mol Sci. 2023;24:15990.
    PubMed    
    Abstract available

  130. RUIZ DE PORRAS V, Font A
    Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers.
    Int J Mol Sci. 2023;24:15795.
    PubMed    
    Abstract available

  131. ALSOFYANI AA, Nedjadi T
    Gelsolin, an Actin-Binding Protein: Bioinformatic Analysis and Functional Significance in Urothelial Bladder Carcinoma.
    Int J Mol Sci. 2023;24:15763.
    PubMed    
    Abstract available

  132. GARCIA-VALLICROSA C, Falcon-Perez JM, Royo F
    The Role of Longevity Assurance Homolog 2/Ceramide Synthase 2 in Bladder Cancer.
    Int J Mol Sci. 2023;24:15668.
    PubMed    
    Abstract available

  133. GAO Y, Wang X, Luo H, Chen C, et al
    Exosomal Long Non-Coding Ribonucleic Acid Ribonuclease Component of Mitochondrial Ribonucleic Acid Processing Endoribonuclease Is Defined as a Potential Non-Invasive Diagnostic Biomarker for Bladder Cancer and Facilitates Tumorigenesis via the miR-206
    Cancers (Basel). 2023;15:5305.
    PubMed    
    Abstract available

  134. HUANG N, Peng L, Yang J, Li J, et al
    FAM111B Acts as an Oncogene in Bladder Cancer.
    Cancers (Basel). 2023;15:5122.
    PubMed    
    Abstract available

  135. YILDIZ AK, Oktem C, Keseroglu BB, Kacan T, et al
    A New Scoring System to Differentiate Bladder Cancer from Intravesical Prostatic Protrusion in the Bladder Neck: BCa-IPP Score.
    Curr Med Imaging. 2023 Nov 10. doi: 10.2174/0115734056241577231023064014.
    PubMed    
    Abstract available

  136. STRAUB M, Auderset A, de Leval L, Piazzon N, et al
    Nitrogen isotopic composition as a gauge of tumor cell anabolism-to-catabolism ratio.
    Sci Rep. 2023;13:19796.
    PubMed    
    Abstract available

  137. SUNGU N, Kiran MM
    Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency.
    Pol J Pathol. 2023;74:161-170.
    PubMed    
    Abstract available

  138. ZHOU G, Qin G, Zhang Z, Zhao H, et al
    Identification of tryptophan metabolism- and immune-related genes signature and prediction of immune infiltration landscape in bladder urothelial carcinoma.
    Front Immunol. 2023;14:1283792.
    PubMed    
    Abstract available

  139. MOLLER CT, Tafjord G, Blindheim A, Berge V, et al
    Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway.
    Scand J Urol. 2023;58:101-108.
    PubMed    
    Abstract available

  140. SODAGUM L, Passarelli R, Pfail J, Patel HV, et al
    Pelvic lymphadenectomy: Evaluating nodal stage migration and will rogers effect in bladder cancer.
    Urol Oncol. 2023 Nov 10:S1078-1439(23)00324.
    PubMed    
    Abstract available

  141. WANG J, Li X, Chen S, Cao J, et al
    Identification of the role of MCM6 in bladder cancer prognosis, immunotherapy response, and in vitro experimental investigation using multi-omics analysis.
    Life Sci. 2023;335:122253.
    PubMed    
    Abstract available

  142. WANG J, Zuo Z, Yu Z, Chen Z, et al
    Collaborating single-cell and bulk RNA sequencing for comprehensive characterization of the bladder cancer intratumor heterogeneity and prognostic model development for bladder cancer.
    Aging (Albany NY). 2023;15.
    PubMed    
    Abstract available

  143. WAN H, Zhan X, Li X, Chen T, et al
    Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer.
    BMC Urol. 2023;23:182.
    PubMed    
    Abstract available

  144. LI Y, Liu Y, Kang Z, Guo J, et al
    Tumor microenvironment heterogeneity in bladder cancer identifies biologically distinct subtypes predicting prognosis and anti-PD-L1 responses.
    Sci Rep. 2023;13:19563.
    PubMed    
    Abstract available

  145. LIANG H, Yang Q, Sun H, Xu Y, et al
    The vascular and morphological characteristics of tumors under narrow-band imaging as predictors for the grade and stage of bladder cancer: a prospective and multi-center study.
    Ann Med. 2023;55:2281656.
    PubMed    
    Abstract available

  146. SANTINI D, Banna GL, Buti S, Isella L, et al
    Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts.
    Curr Oncol Rep. 2023;25:1345-1362.
    PubMed    
    Abstract available

  147. KIM JM, Choi E, Sung SH, Kang H, et al
    Invasive urothelial carcinoma with chordoid features or abundant myxoid stroma: A reappraisal of morphologic spectrum and risk stratification based on molecular classification.
    Pathol Res Pract. 2023;251:154839.
    PubMed    
    Abstract available

  148. DLUBAK A, Karwacki J, Logon K, Tomecka P, et al
    Lymph Node Dissection in Upper Tract Urothelial Carcinoma: Current Status and Future Perspectives.
    Curr Oncol Rep. 2023;25:1327-1344.
    PubMed    
    Abstract available

  149. EMINAGA O, Lee TJ, Laurie M, Ge TJ, et al
    Efficient Augmented Intelligence Framework for Bladder Lesion Detection.
    JCO Clin Cancer Inform. 2023;7:e2300031.
    PubMed    
    Abstract available

  150. RICH JM, Tillu N, Grauer R, Busby D, et al
    Robot-Assisted Repair of Ureteroenteric Strictures After Cystectomy with Urinary Diversion: Technique Description and Outcomes from the European Robotic Urology Section Scientific Working Group.
    J Endourol. 2023;37:1209-1215.
    PubMed    
    Abstract available

  151. IWASAKI S, Takahashi K, Katano H, Suzuki T, et al
    BK Polyomavirus-Associated Urothelial Carcinoma of the Bladder with a Background of BK Polyomavirus Nephropathy in a Kidney Transplant Recipient.
    Nephron. 2023;147 Suppl 1:53-60.
    PubMed    
    Abstract available

  152. WU B, Zhou X
    LncRNA UCA1 could regulate the progression of neuropathic pain by regulating miR-135a-5p.
    Mutat Res. 2023;827:111833.
    PubMed    
    Abstract available

  153. CELIK S, Aktas T, Gokbayrak O, Erol A, et al
    Genomic Alterations of Signaling and DNA Damage Repair Pathways in Non-muscle Invasive Bladder Cancer.
    Cancer Invest. 2023 Nov 24:1-10. doi: 10.1080/07357907.2023.2288640.
    PubMed    
    Abstract available

  154. JIANG Z, Wang Y, Tuo Z
    Comprehensive analysis of Transferrin receptor (TFRC): A prognostic biomarker for patients with bladder cancer.
    Asian J Surg. 2023 Nov 22:S1015-9584(23)01835.
    PubMed    


  155. BEEREN I, Klerks NE, Aben KK, Oddens JR, et al
    Health-related Quality of Life During the First 4 Years After Non-Muscle-invasive Bladder Cancer Diagnosis: Results of a Large Multicentre Prospective Cohort.
    Eur Urol Oncol. 2023 Nov 22:S2588-9311(23)00252.
    PubMed    
    Abstract available

  156. WANG D, Ning H, Wu H, Song Y, et al
    Construction and evaluation of a novel prognostic risk model of aging-related genes in bladder cancer.
    Curr Urol. 2023;17:236-245.
    PubMed    
    Abstract available

  157. GADELKAREEM RA, Abdelraouf AM, Ahmed AI, El-Taher AM, et al
    Predictors of time-to-nadir serum creatinine after drainage of bilaterally obstructed kidneys due to bladder cancer.
    Curr Urol. 2023;17:246-250.
    PubMed    
    Abstract available

  158. IEMURA Y, Miyake M, Fukui S, Fujii T, et al
    Depth of invasion to the bladder wall as a prognostic factor and its association with circulating cell-free DNA levels in patients with muscle-invasive bladder cancer.
    Curr Urol. 2023;17:229-235.
    PubMed    
    Abstract available

  159. DI GIANFRANCESCO L
    The association between postvoid residual and response to standard therapy in male and female patients with non-muscle-invasive bladder cancer.
    Curr Urol. 2023;17:251-256.
    PubMed    
    Abstract available

  160. JIANG Y, Sun X, Song X, Li Z, et al
    Patient-derived bladder cancer organoid model to predict sensitivity and feasibility of tailored precision therapy.
    Curr Urol. 2023;17:221-228.
    PubMed    
    Abstract available

  161. LIEDBERG F, Xylinas E, Gontero P
    Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Guerin Instillations for Bladder Cancer: Time To Reconsider the Evidence and Open the Quinolone Box?
    Eur Urol Focus. 2023 Nov 21:S2405-4569(23)00249.
    PubMed    
    Abstract available

  162. MYERS A, Ristau B, Mossanen M, Tyson MD, et al
    Patient reported treatment burden and attitudes towards in-home intravesical therapy among patients with bladder cancer.
    Urol Oncol. 2023 Nov 21:S1078-1439(23)00306.
    PubMed    
    Abstract available

  163. ZHENG B, Niu L, Xu H, Yang Y, et al
    Engineering redirected NF-kappaB/OIP5 expression programs to enhance tumor responses to chemotherapy in bladder cancer.
    Sci Bull (Beijing). 2023 Nov 14:S2095-9273(23)00781.
    PubMed    
    Abstract available

  164. ZHOU Y, Borcsok J, Adib E, Kamran SC, et al
    ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.
    Sci Adv. 2023;9:eadg2263.
    PubMed    
    Abstract available

  165. HERZEEL C, D'Hondt E, Vandeweerd V, Botermans W, et al
    A software package for efficient patient trajectory analysis applied to analyzing bladder cancer development.
    PLOS Digit Health. 2023;2:e0000384.
    PubMed    
    Abstract available

  166. WANG Z, He W, Ying Y, Wang M, et al
    Patients With Muscle-Invasive Bladder Cancer With Lymphovascular Invasion in Transurethral Resection Specimen Benefits Most From Platinum-Based Neoadjuvant Chemotherapy.
    Clin Genitourin Cancer. 2023 Nov 2:S1558-7673(23)00234.
    PubMed    
    Abstract available

  167. ZENGZHAO W, Xuan L, Xiaohan M, Encun H, et al
    Molecular mechanism of microRNAs, long noncoding RNAs, and circular RNAs regulating lymphatic metastasis of bladder cancer.
    Urol Oncol. 2023 Nov 20:S1078-1439(23)00351.
    PubMed    
    Abstract available

  168. KOLL FJ, Doring C, Herwig L, Hoeh B, et al
    Impact of consensus molecular subtypes on survival with and without adjuvant chemotherapy in muscle-invasive urothelial bladder cancer.
    J Clin Pathol. 2023 Nov 21:jcp-2023-208973. doi: 10.1136/jcp-2023-208973.
    PubMed    
    Abstract available

  169. LIU G, Zhang T, Gui D, Liu Q, et al
    Clinical significance and immune landscape of angiogenesis-related genes in bladder cancer.
    Aging (Albany NY). 2023;15.
    PubMed    
    Abstract available

  170. BALINT IB, Erdodi BT
    Is there a promoting role for artificial sweeteners in the evolution of bladder cancer? A meta-analysis of current literature.
    Minerva Surg. 2023 Nov 21. doi: 10.23736/S2724-5691.23.10000.
    PubMed    
    Abstract available

  171. POSFAI B, Santa F, Schubert A, Semjen D, et al
    [Morphological variants of the invasive urothelial cell carcinoma.].
    Orv Hetil. 2023;164:1567-1582.
    PubMed    
    Abstract available

  172. SAHU R, Shah K, Malviya R, Paliwal D, et al
    E-Cigarettes and Associated Health Risks: An Update on Cancer Potential.
    Adv Respir Med. 2023;91:516-531.
    PubMed    
    Abstract available

  173. MALMSTROM PU, Truls G
    Abandoning testing for asymptomatic microscopic haematuria in Sweden - a long-term follow-up.
    Scand J Urol. 2023;58:109-114.
    PubMed    
    Abstract available

  174. MALLET R
    Thulium fiber laser as a novel technique with shallow and accurate cutting, high-quality hemostasis, and no ballistic effect in the treatment of non-muscle invasive bladder cancer.
    Urologia. 2023 Nov 20:3915603231211982. doi: 10.1177/03915603231211982.
    PubMed    


  175. DAUNGSUPAWONG H, Wiwanitkit V
    Knowledge-map analysis and bladder cancer immunotherapy: Comment.
    Hum Vaccin Immunother. 2023;19:2285094.
    PubMed    


  176. DENG W, Chen R, Xiong S, Nie J, et al
    CircFSCN1 induces tumor progression and triggers epithelial-mesenchymal transition in bladder cancer through augmentation of MDM2-mediated p53 silencing.
    Cell Signal. 2023 Nov 17:110982. doi: 10.1016/j.cellsig.2023.110982.
    PubMed    
    Abstract available

  177. VAISHAMPAYAN UN, Heilbrun L, Vaishampayan N, Harper FW, et al
    Phase II trial of Concurrent Nivolumab and Radiation therapy in Elderly or Chemotherapy ineligible Muscle Invasive Bladder Cancer.
    Int J Radiat Oncol Biol Phys. 2023 Nov 17:S0360-3016(23)08152.
    PubMed    
    Abstract available

  178. KOMURA K, Hirosuna K, Tokushige S, Tsujino T, et al
    The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
    Mol Cancer. 2023;22:185.
    PubMed    
    Abstract available

  179. LIU CH, Zhang JJ, Zhang QJ, Dong Y, et al
    METTL3 regulates the proliferation, metastasis and EMT progression of bladder cancer through P3H4.
    Cell Signal. 2023;113:110971.
    PubMed    
    Abstract available

  180. BASILE G, Pradere B, Lenfant L, Roupret M, et al
    Re: Katharina Bruck, Richard P. Meijer, Joost L. Boormans, et al. Disease-free Survival of Patients with Muscle-invasive Bladder Cancer Treated with Radical Cystectomy Versus Bladder-preserving Therapy: A Nationwide Study. Int J Radiat Oncol Biol Phys
    Eur Urol Oncol. 2023 Nov 15:S2588-9311(23)00238.
    PubMed    


  181. XU C, Cao J, Zhou T
    Radiogenomics uncovers an interplay between angiogenesis and clinical outcomes in bladder cancer.
    Environ Toxicol. 2023 Nov 17. doi: 10.1002/tox.24038.
    PubMed    
    Abstract available

  182. CIVI CETIN K, Oner S, Erdogan B, Simsek G, et al
    Young population bladder neoplasms.
    Eur Rev Med Pharmacol Sci. 2023;27:10454-10461.
    PubMed    
    Abstract available

  183. ZHONG X, Pan Y, Wu K, Wang L, et al
    A novel nomogram based on body composition and nutritional indicators to predict the prognosis of patients with muscle-invasive bladder cancer undergoing radical cystectomy.
    Cancer Med. 2023 Nov 16. doi: 10.1002/cam4.6712.
    PubMed    
    Abstract available

  184. GARG T, Frank K, Johns A, Rabinowitz K, et al
    Geriatric assessment-derived deficit accumulation and patient-reported treatment burden in older adults with bladder cancer.
    J Am Geriatr Soc. 2023 Nov 16. doi: 10.1111/jgs.18676.
    PubMed    
    Abstract available

  185. SRETENOVIC M, Lisicic N, Bulat P, Radisavcevic D, et al
    Prognostic value of preoperative De Ritis ratio on oncological outcomes in patients with muscle-invasive bladder cancer.
    J Surg Oncol. 2023 Nov 16. doi: 10.1002/jso.27517.
    PubMed    
    Abstract available

  186. KIKUCHI H, Abe T, Miyake M, Miyata H, et al
    The impact of second transurethral resection on survival outcomes in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin therapy.
    Jpn J Clin Oncol. 2023 Nov 16:hyad155. doi: 10.1093.
    PubMed    
    Abstract available


  187. [Not Available].
    Aktuelle Urol. 2023;54:438-440.
    PubMed    



  188. [Not Available].
    Aktuelle Urol. 2023;54:428-430.
    PubMed    



  189. [Not Available].
    Aktuelle Urol. 2023;54:428.
    PubMed    


  190. ZHANG H, Li D, Chen C
    Comment on: Vitamin C and catheter-related bladder discomfort after transurethral resection of bladder tumor: A double-blind, randomized, placebo-controlled study.
    J Clin Anesth. 2024;92:111273.
    PubMed    


  191. HUANG H, Xu Q, Zhang Y, Zhou Y, et al
    miR-628-5p is a Potential Novel Prognosis Biomarker, Associated with Immune Infiltration in Bladder Urothelial Carcinoma.
    Curr Pharm Des. 2023;29:2477-2488.
    PubMed    
    Abstract available

  192. LORIOT Y, Matsubara N, Park SH, Huddart RA, et al
    Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    N Engl J Med. 2023;389:1961-1971.
    PubMed    
    Abstract available

  193. CHAPUR J, Kojic K, Kula M, Flexman AM, et al
    Perioperative cortical hand stroke syndrome mimicking peripheral neuropathy: a case report.
    Can J Anaesth. 2023;70:1839-1844.
    PubMed    
    Abstract available

  194. QIANG Z, Jubber I, Lloyd K, Cumberbatch M, et al
    Gene of the month: GATA3.
    J Clin Pathol. 2023;76:793-797.
    PubMed    
    Abstract available

  195. GHATALIA P, Plimack ER
    Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma.
    Nat Rev Clin Oncol. 2023;20:818-819.
    PubMed    


  196. NISHIYAMA N, Kita Y, Ito K, Kato M, et al
    Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
    Anticancer Res. 2023;43:5041-5050.
    PubMed    
    Abstract available

  197. VON DEIMLING M, Furrer M, Mertens LS, Mari A, et al
    Impact of the Extent of Lymph Node Dissection on Survival Outcomes in Clinically Lymph Node-Positive Bladder Cancer.
    BJU Int. 2023 Oct 30. doi: 10.1111/bju.16210.
    PubMed    
    Abstract available

  198. ZHAO Y, Chen J, Zheng H, Luo Y, et al
    SUMOylation-driven mRNA circularization enhances translation and promotes lymphatic metastasis of bladder cancer.
    Cancer Res. 2023 Nov 22. doi: 10.1158/0008-5472.CAN-23-2278.
    PubMed    
    Abstract available

  199. DRAKAKI A, Powles T, Bamias A, Martin-Liberal J, et al
    Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
    Clin Cancer Res. 2023;29:4373-4384.
    PubMed    
    Abstract available

  200. LERNER SP, McConkey DJ, Tangen CM, Meeks JJ, et al
    Association of Molecular Subtypes with Pathologic Response, PFS and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2023 Nov 15. doi: 10.1158/1078-0432.CCR-23-0602.
    PubMed    
    Abstract available

  201. GUERCIO BJ, Sarfaty M, Teo MY, Ratna N, et al
    Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
    Clin Cancer Res. 2023;29:4586-4595.
    PubMed    
    Abstract available

  202. WANG Z, Zeng S, Xu C
    Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
    Eur Urol. 2023 Oct 31:S0302-2838(23)03169-X. doi: 10.1016/j.eururo.2023.
    PubMed    


  203. HENSLEY PJ, Choudhury A, Khaki AR, Grivas P, et al
    The 2023 European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: A Critical Appraisal.
    Eur Urol. 2023 Oct 31:S0302-2838(23)03208-6. doi: 10.1016/j.eururo.2023.
    PubMed    


  204. MORI K
    Editorial Comment from Dr. Mori to texture feature analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:1059.
    PubMed    


  205. CHEN W, Yokoyama M, Waseda Y, Kobayashi M, et al
    Surgical outcomes of robot-assisted radical cystectomy in octogenarian or older patients: A Japanese nationwide study.
    Int J Urol. 2023;30:1014-1019.
    PubMed    
    Abstract available

  206. KANEKO H, Fujiwara M, Tanaka H, Kimura K, et al
    Texture feature analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:1056-1058.
    PubMed    


  207. TOMIYAMA E, Fujita K, Hashimoto M, Uemura H, et al
    Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
    Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15338.
    PubMed    
    Abstract available

  208. ROSAZZA M, Soria F, Gontero P
    Editorial comment-Risk stratification and management of nonmuscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
    Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15340.
    PubMed    


  209. NUNES FM, Apolonio JD, Mota-Pinto A, Leao R, et al
    Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
    Int J Urol. 2023 Nov 14. doi: 10.1111/iju.15335.
    PubMed    
    Abstract available

  210. MIYAKE M, Nishimura N, Nishioka Y, Fujii T, et al
    Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer.
    Int Urol Nephrol. 2023 Nov 1. doi: 10.1007/s11255-023-03851.
    PubMed    
    Abstract available

  211. BEIJERT IJ, Hentschel AE, Brundl J, Comperat EM, et al
    Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?
    Int Urol Nephrol. 2023 Nov 19. doi: 10.1007/s11255-023-03867.
    PubMed    
    Abstract available

  212. SOOD A, Rudzinski JK, Labbate CV, Hensley PJ, et al
    Long-Term Oncological Outcomes in Patients Diagnosed with Non-Metastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience.
    J Urol. 2023 Nov 3:101097JU0000000000003778. doi: 10.1097/JU.0000000000003778.
    PubMed    
    Abstract available

  213. RAMAL M, Corral S, Kalisz M, Lapi E, et al
    The urothelial gene regulatory network: understanding biology to improve bladder cancer management.
    Oncogene. 2023 Nov 23. doi: 10.1038/s41388-023-02876.
    PubMed    
    Abstract available

  214. SONG W, Li Z, Xia M, Xiao W, et al
    Regulation of Drp1 and enhancement of mitochondrial fission by the deubiquitinating enzyme PSMD14 facilitates the proliferation of bladder cancer cells.
    Oncol Rep. 2024;51:6.
    PubMed    
    Abstract available

  215. ARNAUD Q, Sebe P, Colau A, Mouton M, et al
    Management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection: A retrospective study comparing Bacillus Calmette-Guerin therapy upfront versus a third resection.
    Prog Urol. 2023 Nov 16:S1166-7087(23)00238-5. doi: 10.1016/j.purol.2023.
    PubMed    
    Abstract available

  216. SHEN C, Zhang DL, Cheng XL, Zhang WC, et al
    Urological Tumor: A Narrative Review of Tertiary Lymphatic Structures.
    Urol Int. 2023;107:841-847.
    PubMed    
    Abstract available

  217. YUAN P, Li X, Yuan Y, Xu P, et al
    Successful Kidney-Sparing Systemic Therapy for a High-Risk Ureteral Carcinoma Case.
    Urol Int. 2023;107:895-898.
    PubMed    
    Abstract available

  218. GUO L, Zhang T, Taisheng L, Chen J, et al
    Laparoscopic Radical Cystectomy With Ileal Orthotopic Neobladder for Bladder Cancer: Current Indications and Outcomes.
    Urol Int. 2023 Nov 23. doi: 10.1159/000535032.
    PubMed    
    Abstract available

  219. GALOSI AB, Fave RFD, Perpepaj L, Milanese G, et al
    Does Alexis(c) wound protector/retractor reduce the risk of surgical site infections after open radical cystectomy for bladder cancer? Results from a single center, comparative study.
    Urology. 2023 Nov 6:S0090-4295(23)00951-2. doi: 10.1016/j.urology.2023.
    PubMed    
    Abstract available

  220. ARCEO-OLAIZ R, Smith EA, Stokes C, Eaton BR, et al
    Use of Perirectal Hyaluronic Acid Spacer Prior to Radiotherapy in a Pediatric Patient With Bladder Rhabdomyosarcoma: A Case Report.
    Urology. 2023;181:136-140.
    PubMed    
    Abstract available

  221. TUA-CARACCIA R, Livingston A, Routh JC
    Recurrent Papillary Bladder Tumors in a Boy With Lynch Syndrome.
    Urology. 2023;181:133-135.
    PubMed    
    Abstract available

  222. LI Y, Xu K, Zhang Y, Mao H, et al
    Identification of a basement membrane-related genes signature with immune correlation in bladder urothelial carcinoma and verification in vitro.
    BMC Cancer. 2023;23:1021.
    PubMed    
    Abstract available

  223. LU L, Chen C, Cheng H, Ding H, et al
    Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1066.
    PubMed    
    Abstract available

  224. ROUSSOT N, Fumet JD, Limagne E, Thibaudin M, et al
    A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
    BMC Cancer. 2023;23:1080.
    PubMed    
    Abstract available

  225. GORE JL, Wolff EM, Comstock BA, Follmer KM, et al
    Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
    BMC Cancer. 2023;23:1127.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;